The majority of older women in nursing homes are likely to be deficient in vitamin D during winter months, and those with the lowest levels are at a significantly increased risk of death, according to a study published online February 8, in the Journal of Clinical Endocrinology.
The majority of older women in nursing homes are likely to be deficient in vitamin D during winter months, and those with the lowest levels are at a significantly increased risk of death, according to a study published online February 8, in the Journal of Clinical Endocrinology & Metabolism.
Vitamin D deficiency is extraordinarily high among nursing-home residents, stated lead investigator Stefan Pilz, of the Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria, and colleagues.
“Limited sunlight access in concert with impaired vitamin D synthesis of the aging skin as well as nutritional deficits may likewise contribute to this high prevalence of vitamin D deficiency,” the authors said.
And, although 25-hydroxyvitamin D (25[OH]D) concentrations are associated with an increased risk of death in the general population, there is only 1 study looking at the measurement for nursing-home patients. As a result, the researchers conducted a prospective cohort study to evaluate whether 25(OH)D concentrations are associated with mortality in elderly female nursing-home patients.
The researchers examined 961 female patients from 95 nursing homes in Austria and found 92.8% had 25(OH)D levels below the recommended level of 50 nmol/L. After a mean follow-up time of 27 months, the researchers noted 264 patient deaths (30% of the study cohort). These results, they said, are in line with previous studies, suggesting that although well known, there have been no strategies put in place to prevent and treat vitamin D deficiency in this population.
“In view of these findings and the existing literature on adverse effects of vitamin D deficiency, there exists now an urgent need for effective strategies to improve vitamin D status in older institutionalized patients,” the authors concluded. And, although they acknowledge limitations of the study, they stated that it would be reasonable to initiate supplementation in this population.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More